> xymogen cetyl myristoleate

This is the Original, Patented Myristin™ CM / CMO Myristin™ cetyl myristoleate (also known as CMO or CM) was discovered by Harry W. Diehl. Diehl took a fatty acid, myristoleic acid, and combined it with a fatty alcohol molecule, cetyl alcohol, creating an ester of that fatty acid called cetyl myristoleate. He discovered that it was the presence of this compound in swiss albino mice that prevented the mice from developing joint problems. Diehl's laboratory experiments on CM were published in the Journal of Pharmaceutical Sciences in March, 1994. Diehl patented his discover of Myristin, US Patent # 5,569,676. Myristin™ is Diehl's patented and trademarked product, and it is cis-9-cetyl myristoleate, the substance used in Diehl's oft cited research that appeared in the Journal of Pharmaceutical Sciences in March 1994. It is also the substance used (and given orally) in a 32-week, randomized, double blind, placebo- controlled clinical trial by Siemandi, MD, PhD (et al). Myristin™ CM / CMO Protocol One course may be enough for some individuals. Research has indicated an overall success rate as high as 88.2 percent (compared to only 16.1% in the placebo groups) when used in conjunction with supportive nutrients for cartilage growth and control of histamine and leukotrine response (i.e., glucosamine hydrochloride, sea cucumber, and hydrolyzed cartilage). Those individuals who do not have success with CM usually just need more of it; early research indicates that the effectiveness of one course will depend on the severity of the joint condition. Some people have reported improvements in just 7 days. There are no confirmed reports of adverse side effects with Myristin™, nor have there been any reported interactions with other medications or natural substances.